Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president

In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According...

Column: ”Cheating with pea flowers and does it matter whether you are right?”

Is it possible to forgive shortcuts or outright cheating in science - if it turns out that the researcher was ultimately right? Anna Törner discuss this topic in a column.

Pharma Relations AB

The first Lyme disease vaccine faces a delay

Pfizer and Valneva’s Lyme disease vaccine, which could be the first of its kind, is facing delays of about a year. The reason is problems at trial sites in the ...

“We need to build flexible operating theatres”

Flexible operating theatres, micro-sensors on surgeons to monitor their well-being and 3D images projected onto organs to be operated on. These are a few ideas ...

Från apotekare till poddare – Magnus Lejelöv har rösten som verktyg

Magnus Lejelöv har över 20 års erfarenhet från läkemedelssektorn och har intervjuat nära två hundra vårdprofiler i sina poddar. I maj står han på scenen i Lund ...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2026)

How to optimise your liquid handling results

In dispensing or pipetting applications in laboratory automation, it is important to obtain reliable results, which are analysed by calculating the accuracy and...

High-performance Slide Scanner for Fluorescence, Brightfield and Polarization

ZEISS Axioscan 7.

Kris för hajpat genredigeringsbolag – ”Stämningen har skiftat”

Upp som en sol, ner som en pannkaka. Så kan utvecklingen för det upphaussade amerikanska genredigeringsbolaget Tome Biosciences beskrivas.

Ny chefredaktör på Läkartidningen

Åsa Uhlin har utsetts till ny chefredaktör på Läkartidningen efter avgående Pär Sandell.

Festo Expands its Portfolio with Multilayer Manifolds

Manufacturers of medical and laboratory equipment now receive solutions from a single source

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

Vinnova is going to establish a new innovation cluster

Vinnova, the Swedish Agency for Innovation Systems, has been commissioned by the government to establish a national innovation cluster for advanced medicines.

CROs in drug development: "We use our expertise to speed up the process

Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that i...

Aqilions licensdeal gav eko – ”Det var ett litet svenskt biotech som gjorde det”

Var extremt noga med dina vetenskapliga data, men lägg minst lika mycket tid och kraft på affärsutveckling. Det rådet ger Aqilions vd Sarah Fredriksson till bio...

Optimize Courier SUPPLIERS (DISTRIBUTORS)

About Microscope Ergonomics

Learn about ergonomic microscope design and how you can increase your well-being and productivity when working in clinical microscopy. Read about challenges, de...

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...

A surprising discovery about the immune system in cases of cancer

Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising d...

Neanderthal gene variants may cause Viking disease

A new study suggests that the so-called Viking disease, which affects the hand function in many older people, may be linked to gene variants inherited from Neanderthals.

New features in ZEISS CALYPSO 2024

ZEISS CALYPSO is your universal software for dimensional metrology applications.

Cytel Sweden

Nordic Regulatory experts: Improving biotech chances of Succ

Why is it that so many biotech companies fail? And what are the tools needed to change that fact?